Compare Johnson & Johnson (JNJ) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Opendoor Technologies Inc — how do they compare? Johnson & Johnson trades at $260.9 (market cap $618.09B), while Opendoor Technologies Inc trades at $2.23 (market cap $2.22B). The key difference: Johnson & Johnson is far larger — about 278.4× Opendoor Technologies Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Opendoor Technologies Inc for 33 Days on average.
| JNJ | OPEN | |
|---|---|---|
Market Cap | $618.09B | $2.22B |
Volume | 6,050,983 | 28,705,892 |
Sector | Health | Real Estate |
52-Week High | $278.43 | $9.37 |
52-Week Low | $186.00 | $2.27 |
Typical Hold Time | 129 Days | 33 Days |
Enterprise Value | $646.37B | $3.29B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Opendoor Technologies (OPEN) trades at $2.215, down 2.42% on the day, reflecting ongoing challenges in the iBuying sector. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentals reveal significant losses with a -46.74% net income margin and -$1.3B net loss in 2025. Recent news highlights mortgage expansion efforts and housing market sensitivity to interest rate fluctuations, with the company aiming for adjusted net income breakeven at a $9B revenue run rate.
Despite trading near analyst consensus price target of $4.92 (122% upside), OPEN faces substantial execution risks amid persistent losses and high debt levels. The bullish case relies on successful mortgage expansion and housing market recovery, but current financial metrics and technical indicators suggest continued volatility. Investors should weigh the significant discount to analyst targets against the company's challenging path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
